Artiva Biotherapeutics
4747 Executive Drive
Suite 1150
San Diego
California
92121
United States
26 articles with Artiva Biotherapeutics
-
Artiva Biotherapeutics Receives FDA Fast Track Designation for AB-101
1/31/2023
Artiva Biotherapeutics, Inc., a clinical stage company whose mission is to deliver highly effective, off-the-shelf, allogeneic natural killer (NK) cell-based therapies, announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Artiva’s lead program AB-101.
-
Artiva Biotherapeutics Presents Preclinical Data for AB-101, an Optimized Allogeneic NK Cell Therapy Candidate, at SITC 2022 Annual Meeting
11/10/2022
Artiva Biotherapeutics, Inc. announced today the presentation of activity and efficacy preclinical data for AB-101 with several combinations of therapeutic monoclonal antibodies in multiple preclinical models of cancer.
-
Artiva Announces Abstract Accepted for Presentation at the 64th American Society of Hematology Annual Meeting & Exposition
11/3/2022
Artiva Biotherapeutics, Inc. announced today the presentation of preclinical efficacy data combining anti-CD38 antibodies with AB-101, the Company’s clinical-stage ADCC-enhancer product candidate, in multiple myeloma models.
-
Affimed and Artiva Biotherapeutics Announce Partnership to Advance Combination Therapy of Innate Cell Engager (ICE®) AFM13 and Off-the-Shelf Allogeneic NK Cell Therapy AB-101
11/3/2022
Affimed N.V. (Nasdaq: AFMD) (“Affimed”), and Artiva Biotherapeutics Inc. (“Artiva”), both immuno-oncology companies focused on developing and commercializing therapies utilizing the innate immune system, today announced a new strategic partnership to jointly develop, manufacture, and commercialize a combination therapy comprised of Affimed’s Innate Cell Engager (ICE®) AFM13 and Artiva’s cord blood-derived, cryopreserved off-the-shelf allogeneic NK cell product candidate, AB-101.
-
Artiva Announces AB-101 Abstract Accepted for Presentation at Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting
10/5/2022
Artiva Biotherapeutics, Inc. announced today that an abstract highlighting further in vivo and in vitro preclinical data for AB-101, the Company’s clinical-stage ADCC-enhancer product candidate, was accepted for presentation at the Society for Immunotherapy of Cancer (SITC).
-
The U.S. FDA had a busy week with a range of drug approvals, advisory committee meetings and classification announcements.
-
Artiva Biotherapeutics Announces FDA Allowance of IND for AB-201, a HER2-Targeted CAR-NK for the Treatment of Solid Tumors
9/20/2022
Artiva Biotherapeutics, Inc. announced today that the U.S. Food and Drug Administration (FDA) has cleared the company’s investigational new drug (IND) application for AB-201.
-
Artiva Biotherapeutics Celebrates Official Opening of San Diego Corporate Headquarters and R&D Lab Facilities
6/13/2022
Artiva Biotherapeutics, Inc., an oncology company whose mission is to deliver highly effective, off-the-shelf allogeneic, natural killer cell therapies that are safe and accessible to cancer patients, announced the official opening of the company’s U.S. corporate headquarters and R&D laboratory facilities at the Alexandria Tech Center in San Diego.
-
Artiva Biotherapeutics Appoints Dr. Thorsten Graef as Chief Medical Officer
6/6/2022
Artiva Biotherapeutics, Inc., an oncology company whose mission is to deliver highly effective, off-the-shelf allogeneic natural killer cell therapies that are safe and accessible to cancer patients, announced the appointment of Thorsten Graef, M.D., Ph.D., as Chief Medical Officer.
-
Artiva Biotherapeutics Appoints Edith A. Perez, M.D., to Its Board of Directors and Clinical Advisory Board
5/5/2022
Artiva Biotherapeutics, Inc. today announced the appointment of Edith A. Perez, M.D., as a member of the Company’s Board of Directors.
-
Artiva Biotherapeutics Announces Agreement with Merck to Evaluate Combinations of NK Cells with Tri-Specific NK-Cell Engagers
4/11/2022
Artiva Biotherapeutics, Inc., an oncology company whose mission is to deliver highly effective, off-the-shelf, allogeneic natural killer (NK) cell therapies to treat cancer, announced today that it has entered into an agreement with Merck, known as MSD outside the United States and Canada.
-
Artiva Biotherapeutics Appoints Laura Bessen, M.D., to Its Board of Directors
3/3/2022
Artiva Biotherapeutics, Inc., an oncology company with a mission to deliver highly effective, off-the-shelf, allogeneic natural killer (NK) cell-based therapies that are safe and accessible to cancer patients, today announced the appointment of Laura Bessen, M.D., as an independent member of the Company’s board of directors.
-
Artiva Biotherapeutics Strengthens Leadership Team with the Appointment of Christopher Horan as Chief Technical Operations Officer
1/4/2022
Artiva Biotherapeutics, Inc., an oncology company focused on developing and commercializing primary allogeneic natural killer (NK) cell therapies to treat cancer, today announced the appointment of Christopher Horan as Chief Technical Operations Officer.
-
Artiva Biotherapeutics to Present Preclinical Data for AB-201, a HER2-Targeting CAR-NK Cell Therapy, at SITC 36th Annual Meeting
10/21/2021
Artiva Biotherapeutics, Inc., (“Artiva”) an oncology company focused on developing and commercializing off-the-shelf, allogeneic natural killer (NK) cell-based therapies to treat cancer, today announced an upcoming presentation describing AB-201, an anti-HER2 CAR-NK cell therapy candidate, at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting and Pre-Conference Programs to be held November 10-14, 2021.
-
Artiva Biotherapeutics Demonstrates Its Commitment to Corporate Social Responsibility by Joining Pledge 1% Movement
9/30/2021
Artiva Biotherapeutics, Inc., announced that it has joined Pledge 1%, a global movement that supports the integration of philanthropy into corporate culture by inspiring companies to donate 1% of product, equity, profit, or employee time to causes of their choice.
-
Artiva Biotherapeutics Establishes U.S. Research and Manufacturing Facility for NK Cell Therapy Pipeline Development and Clinical Supply
8/12/2021
Artiva Biotherapeutics, Inc. (“Artiva”), an oncology company focused on developing and commercializing primary allogeneic natural killer (NK) cell therapies to treat cancer, today announced the expansion of the Company’s U.S. facilities in San Diego
-
Artiva Biotherapeutics is quadrupling its footprint in San Diego with a 52,000 square-foot corporate HQ, R&D and manufacturing center opening next year.
-
Artiva Biotherapeutics Appoints Two New Independent Members to Its Board of Directors
5/19/2021
Artiva Biotherapeutics appoints Elizabeth L. Hougen, EVP and CFO of Ionis Pharmaceuticals, Inc., has extensive experience in finance and business for public life sciences companies Linda M. Kozick, who led the immuno-oncology product and portfolio strategy for BMS, including Opdivo ® and Yervoy ® , has deep expertise in strategic commercial drug development
-
Artiva Biotherapeutics Appoints Michael E. Faerm as Chief Financial Officer
4/6/2021
Artiva Biotherapeutics, Inc., an oncology company focused on developing and commercializing primary allogeneic natural killer (NK) cell therapies to treat cancer, today announced the appointment of Michael E. Faerm as Chief Financial Officer.
-
Artiva Biotherapeutics Raises $120 Million in Series B Financing to Advance Pipeline of Allogeneic NK Cell Therapies
2/26/2021
Artiva Biotherapeutics , Inc., an oncology-focused biopharmaceutical company developing cell therapies based on primary allogeneic natural killer (NK) cells that have been optimized for their ability to kill tumors, today announced the closing of a $120 million Series B financing. New investor Venrock Healthcare Capital Partners led the financing.